Company to Exhibit Advancements in At-Home Sleep Therapy and Engage Ear, Nose, and Throat MDs and Leaders on the Future of Patient-Centered Care

Spring Sleep, the flagship consumer brand of Spectrum Sleep Solutions Inc., focused on expanding access to advanced sleep therapies across the U.S., starting with eXciteOSA®, will participate in the AAO-HNSF-2025 Annual Meeting & OTO Expo, taking place October 11–14.

eXciteOSA is the only FDA-cleared daytime treatment for mild to moderate obstructive sleep apnea (OSA). Unlike CPAP and other therapies that only manage symptoms, eXciteOSA uses gentle neuromuscular electrical stimulation (NMES) to strengthen airway muscles – addressing a root cause of OSA.

The Chair of Spring Sleep’s Scientific Advisory Board (SAB) – Dr. David Yen, MD, and Spring Sleep's lead ENT Advisor, Dr. Brian Weeks, MD, both of whom are nationally recognized experts in otolaryngology, will be in attendance to share their expertise on the latest innovations and treatment approaches for obstructive sleep apnea (OSA), including NMES.

AAO-HNSF follows Spring Sleep’s inaugural SAB meeting last month, convening several leading members of the ENT community, including Cleveland Clinic, Stanford Health System, Massachusetts General Hospital, Senta Partners, St. Luke’s, and more. The meeting is being held to discuss and validate eXciteOSA as a viable and lifestyle-friendly treatment for mild to moderate OSA. Select members will continue this conversation and exchange of knowledge at AAO-HNSF.

“We’re thrilled to engage with experts at this year’s AAO-HNSF meeting and deepen our collaboration with the ENT community,” said Forrest Ackerman, CEO of Spectrum Sleep Solutions and Founder of Spring Sleep. “Our mission is to expand access to evidence-based, non-invasive treatments for sleep-disordered breathing, and events like AAO-HNSF provide an invaluable opportunity to collaborate with clinicians who share our commitment to helping patients achieve better sleep health – without masks or surgery.”

During the conference, members of Spring Sleep’s SAB and clinical team will be available at booth #506 to discuss innovation in sleep medicine more broadly and share insights on the role of eXciteOSA in addressing the severe unmet needs of patients with primary snoring or mild OSA.

“As ENTs, we see firsthand how limited current options are for patients with primary snoring and mild OSA,” said Dr. Brian Weeks, member of the Spring Sleep Scientific Advisory Board. “eXciteOSA offers an effective, patient-friendly therapy that integrates seamlessly into our practices. Spring Sleep’s mission to bridge clinical innovation and patient care is a meaningful step forward in improving OSA patient outcomes and quality of life.”

To learn more about eXciteOSA and Spring Sleep’s approach to guide patients toward comprehensive care, please visit springsleep.com.

About Spring Sleep

Spring Sleep is the flagship consumer brand of Spectrum Sleep Solutions Inc., focused on expanding access to advanced sleep therapies across the United States. Its debut product, eXciteOSA®, is the only FDA-cleared daytime treatment for mild to moderate obstructive sleep apnea (OSA). Spring Sleep delivers innovative, non-invasive solutions directly to consumers, providing a seamless and trusted experience. As a bridge between clinical innovation and patient care, Spring Sleep empowers individuals to take control of their sleep health. springsleep.com

About Spectrum Sleep Solutions Inc.

Spectrum Sleep Solutions Inc. is a U.S.-based medical device company focused on non-invasive treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and chronic snoring. Founded in 2024 and headquartered in Fairfax, Virginia, Spectrum Sleep Solutions serves as the B2B distribution and clinical services partner for eXciteOSA®, supporting physicians, durable medical equipment (DME) providers, and health systems nationwide. spectrumsleep.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251009287957/en/